重复肽受体放射治疗转移性神经内分泌肿瘤的多次复发 - Suppr | 超能文献

Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor.

作者信息

Brogsitter Claudia, Zöphel Klaus, Folprecht Gunnar, Eisenhofer Grame, Kotzerke Jörg

出版信息

Nuklearmedizin. 2017 Jun 12;56(3):N19-N21. doi: 10.3413/Nukmed-0863-16-11. Epub 2017 Mar 30.

DOI:10.3413/Nukmed-0863-16-11

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor.重复肽受体放射治疗转移性神经内分泌肿瘤的多次复发

Nuklearmedizin. 2017 Jun 12;56(3):N19-N21. doi: 10.3413/Nukmed-0863-16-11. Epub 2017 Mar 30.

2

Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.基于¹⁷⁷Lu-DOTATATE的肽受体放射性核素治疗在转移性胃肠胰神经内分泌肿瘤中的应用：一项与原发肿瘤部位、肿瘤增殖指数及双示踪剂成像特征相关的多参数反应评估

Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547.

3

Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.肽受体放射性核素治疗在神经内分泌肿瘤治疗中的应用

Hematol Oncol Clin North Am. 2016 Feb;30(1):179-91. doi: 10.1016/j.hoc.2015.09.009.

4

Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?68Ga DOTATOC PET 治疗前肿瘤 SUV 是否可以预测 177Lu 奥曲肽治疗的吸收剂量？

Clin Nucl Med. 2012 Jun;37(6):e141-7. doi: 10.1097/RLU.0b013e31823926e5.

5

Comment on Campana et al.: radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.对坎帕纳等人的评论：放射性标记的生长抑素类似物治疗胃肠胰神经内分泌肿瘤：与反应相关的因素及治疗顺序建议

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):174-5. doi: 10.1007/s00259-013-2599-0. Epub 2013 Nov 6.

6

Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.放射性标记生长抑素类似物治疗胃肠胰神经内分泌肿瘤：与反应相关的因素及治疗顺序建议：对Ezziddin等人评论的回应

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):176-7. doi: 10.1007/s00259-013-2603-8.

7

How We Do It: A Multidisciplinary Approach to Lu DOTATATE Peptide Receptor Radionuclide Therapy.方法介绍：Lu DOTATATE 肽受体放射性核素治疗的多学科方法。

Radiology. 2021 Feb;298(2):261-274. doi: 10.1148/radiol.2020201745. Epub 2020 Nov 24.

8

Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.耐药性起作用和/或进行性有症状的转移性胃肠胰神经内分泌肿瘤：177Lu-DOTATATE肽受体放射性核素治疗在这种情况下的疗效。

Nucl Med Commun. 2018 Dec;39(12):1143-1149. doi: 10.1097/MNM.0000000000000926.

9

Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.比较神经内分泌肿瘤患者 PRRT 后 SPECT/CT 和 68Ga-DOTATOC PET/CT 上基于 SUV 的参数，评估 177Lu-DOTATATE 的临床定量：一项可行性研究。

Clin Nucl Med. 2021 Feb 1;46(2):111-118. doi: 10.1097/RLU.0000000000003412.

10

Evaluation of Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors.评估 Lu-Dotatate 治疗转移性神经内分泌肿瘤患者的疗效和预后因素。

World J Gastroenterol. 2020 Apr 7;26(13):1513-1524. doi: 10.3748/wjg.v26.i13.1513.